GHRP-2 (10 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration (once‑daily schedule).

• Peptide Vials (GHRP-2, 10 mg each):
  • 8 weeks: approximately 1 vial required (~9.1 mg used)
  • 12 weeks: approximately 2 vials required (~15.4 mg used)
  • 16 weeks: approximately 3 vials required (~22.4 mg used)
• Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (1 vial): 3 mL - 1 bottle required (10 mL each)
  • 12 weeks (2 vials): 6 mL - 1 bottle required (10 mL each)
  • 16 weeks (3 vials): 9 mL - 1 bottle required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs - 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs - 3 boxes required (100 swabs each)

Sharps Container: 1‑quart container holds ~100 syringes; 2‑quart for 16‑week protocols.

GHRP-2 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily (gradual titration).
• Easy measuring: At 3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

GHRP-2 (pralmorelin) is a synthetic hexapeptide that potently stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus^[1][2]. It has been used in clinical research as a diagnostic GH stimulant and in investigative treatment protocols for growth hormone deficiency^[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Concise summary of the once‑daily regimen.

• Goal: Stimulate pulsatile growth hormone release and elevate IGF‑1 levels over time^[5].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 100–300 mcg daily with gradual titration.
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; follow product-specific use-by instructions after reconstitution.

Suggested daily titration approach.

• Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated^[3].
• Target: 200 mcg daily by Weeks 5–8; optional increase to 250–300 mcg in Weeks 9–12.
• Frequency: Once per day (subcutaneous); advanced protocols may use 2–3× daily.
• Cycle Length: 8–12 weeks; optional extension to 16 weeks with periodic breaks.
• Timing: Typically before sleep or on empty stomach; rotate injection sites.

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; follow the exact product’s expiration or validated stability information.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Use bacteriostatic water (0.9% benzyl alcohol) for multi‑dose reconstitution.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container^[10].
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[11].
• Inject slowly; wait a few seconds before withdrawing the needle.
• A 5‑days‑on/2‑days‑off schedule may help maintain GH response sensitivity over long protocols^[7].
• Document daily dose and site rotation to maintain consistency.

GHRP-2 is a growth hormone‑releasing peptide that acts as a ghrelin receptor agonist (GHS‑R1a)^[1]. By binding to receptors in both the pituitary and hypothalamus, it triggers robust, pulsatile GH release that mimics natural secretion patterns^[2]. Clinical studies have demonstrated that even a single 100 mcg subcutaneous dose can raise GH levels several‑fold above baseline^[4]. When administered consistently, GHRP-2 can elevate IGF‑1 levels over weeks to months^[5]. However, the GH response may attenuate with continuous daily use (tachyphylaxis), which is why titration strategies and periodic breaks are often incorporated^[4][7].

Observations from preclinical and clinical literature.

Potential Benefits

• Potent stimulation of endogenous GH release without suppressing natural production^[1].
• Elevation of IGF‑1 levels with sustained administration (~50% increase reported in some studies)^[5].
• Used clinically as a diagnostic tool for GH deficiency evaluation^[3].
• May support recovery, body composition, and sleep quality (anecdotally reported).

Potential Side Effects

• Increased appetite (ghrelin‑mimetic action) - especially pronounced shortly after injection^[1].
• Transient flushing, warmth, or tingling at injection site.
• Possible mild increases in cortisol and prolactin at higher doses^[6].
• Water retention or joint stiffness with prolonged high‑dose use.
• Response attenuation (tachyphylaxis) with continuous daily dosing^[4].

Complementary strategies for best outcomes.

• Administer on an empty stomach or before sleep to optimize GH pulse amplitude.
• Pair with a balanced, protein‑forward diet tailored to energy needs and recovery goals.
• Combine resistance training and aerobic activity to support GH/IGF‑1 axis benefits.
• Prioritize 7–9 hours of quality sleep to synergize with natural nocturnal GH secretion.
• Manage stress levels, as elevated cortisol can blunt GH response.

General subcutaneous guidance from clinical best‑practice resources^[10][11].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[11].
• For very lean individuals, use a 45° angle to avoid intramuscular injection^[10].
• Inject slowly and steadily; do not aspirate for subcutaneous injections.
• Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy^[11].
• Dispose of used syringes immediately in a sharps container; never recap needles.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

• 1
  
  Pralmorelin (GHRP-2) - Wikipedia
  - Overview of GHRP-2 mechanism, ghrelin receptor agonism, and physiological effects

  View Source
• 2
  
  PubMed - Growth hormone response to GHRP-2 (PMC3297037)
  - Pituitary and hypothalamic mechanisms of GH release stimulation

  View Source
• 3
  
  Pihoker C. et al. (1995) - J Clin Endocrinol Metab
  - Diagnostic studies with IV and intranasal GHRP-2 in children of short stature

  View Source
• 4
  
  Nijland EA. et al. (1998) - Eur J Endocrinol
  - Five‑day SC GHRP-2 treatment causes response attenuation in young men

  View Source
• 5
  
  Sigalos JT. et al. (2017) - Am J Mens Health (PMC5675260)
  - GH secretagogue therapy raises IGF-1 levels (~50% increase over 3 months)

  View Source
• 6
  
  Arvat et al., Peptides (1997)
  – Human study of GHRP-2 effects on GH, prolactin, ACTH, and cortisol after controlled intravenous administration.

  View Source
• 7
  
  Kim KS et al. (2003) - Asian-Australas J Anim Sci
  - Twice‑daily GHRP-2 effects on IGF-1 and tachyphylaxis patterns

  View Source
• 10
  
  Usach I. et al. (2019) - Adv Ther (PMC6822791)
  - Subcutaneous injection of drugs: factors influencing pain and technique

  View Source
• 11
  
  MedlinePlus - Subcutaneous (SQ) Injections
  - Site selection, angle guidance, and rotation best practices

  View Source
• 15
  
  Pure Lab Peptides - GHRP-2 (10 mg) Product Page
  - Product specifications, quality documentation, and batch COAs

  View Source
• 11
  
  OncoLink - How To Give a Subcutaneous Injection
  - Step‑by‑step technique, pinch method, and disposal guidance

  View Source
• 12
  
  NCBI Bookshelf - Best Practices for Injections
  - Asepsis, preparation, and administration standards

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.